Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  IMAGING AGENTS
A Global Strategic Business Report

This report analyzes the worldwide markets for Imaging Agents in Millions of US$. The major product segments analyzed are Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 67 companies including many key and niche players worldwide such as AMAG Pharmaceuticals Inc., Amersham Plc, Bayer Schering Pharma AG, Bayer HealthCare Pharmaceuticals, Bracco Group, E-Z-EM Inc., Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, EPIX Pharmaceutical Inc., Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-3336  PAGES:    392
PRICE:    $3950  DATE:       May 2008
COMPANIES:  67  MARKET DATA TABLES:   142
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  IMAGING AGENTS (Complete Report) Pages : 392   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
A. Contrast Media.....I-3
X-Ray Contrast Media.....I-3
Magnetic Resonance Imaging (MRI) Contrast Media.....I-3
  
   Ultrasound Contrast Media.....I-4
B. Diagnostic Radiopharmaceuticals.....I-4
  
II. EXECUTIVE SUMMARY88$2250
  1. Industry Overview.....II-19 $900  
   A Quick Primer On Imaging Agents.....II-1
Growth Drivers.....II-1
1$100
   Growth Inhibitors.....II-2
Changing Dynamics of Imaging Agents.....II-2
1$100
   Imaging Agents: Significant Growth Ahead.....II-3 1$100
   Table 1: Worldwide Imaging Agents Market (2003): Percentage Breakdown of Value Sales for Leading Imaging Agents-Omnipaque, Cardiolite, Magnevist, Iopamiron, Ultravist, Myoview, Visipaque, Omniscan, FDG and Others (includes corresponding Graph/Chart).....II-4
Rise of Non-Ionizing Imaging Techniques.....II-4
1$350
   Table 2: Medical Diagnostic Procedures Conducted Worldwide for the Year 2003: Breakdown by Imaging Modality Type - X-ray/CT, MRI, Ultrasound and Radiopharmaceuticals (In Millions) (includes corresponding Graph/Chart).....II-5
Fusion Imaging Modalities: Greater Clinical Benefits.....II-5
Radiopharmaceuticals-An Exotic Tool.....II-5
1$350
   Nanomaterials Taking the Center Stage.....II-6
Gadolinium Coated Nanoparticles- A Promising Imaging Agent.....II-6
A Peek Into the Pricing Dynamics.....II-6
A Synoptic Overview.....II-6
1$100
   Pros & Cons.....II-7
Positive Factors Driving Prices.....II-7
Negative Factors Bearing Down on Prices.....II-7
1$100
   Reimbursements.....II-8
“Under the Umbrella”.....II-8
Europe.....II-8
United States.....II-8
2$200
  2. Market Trends & Issues.....II-104 $400  
   Falling Prices Turn On the Heat.....II-10
X-Ray Contrast Media: Declining Sector.....II-10
MRI Contrast Media: Playing at Center Court.....II-10
Impact Wielded by Ballooning MRI Practices.....II-10
1$100
   Ultrasound Contrast Media: A Rising Star in the Quadrant.....II-111$100
   Fledging Market Battles Teething Challenges.....II-12
PET: A Prime Growth Driver for Radiopharmaceuticals.....II-12
1$100
   Nuclear Medicine: A Potential Growth Avenue for Radiopharmaceuticals.....II-13
Select Cardiology and Oncology Radiopharmaceuticals.....II-13
1$100
  3. Competition.....II-144 $700  
   Market Structure.....II-141$100
   Key Market Metrics.....II-15
Big Guns in the Emerging MRI Market.....II-15
Bayer Schering Pharma AG: A Pioneering Developer of MRI Contrast Agents.....II-15
1$100
   Competitive Scenario – A Recent Past Perspective.....II-16
Table 3: Worldwide Imaging Agents Market (2004): Percentage Breakdown of Value Sales for Leading Players- GE Healthcare, Bracco, Tyco Healthcare/Mallinckrodt, Schering, BMS and Others (includes corresponding Graph/Chart).....II-16

Table 4: X-ray Medical Diagnostics Market Worldwide: Percentage Market Share of Leading Players for the Years 2002, 2003, and 2004 – Amersham, Bracco, Tyco/ Mallinckrodt, Inc, Schering, Guerbet and Others (Revenue Share) (includes corresponding Graph/Chart).....II-16
1$350
   Table 5: MRI Diagnostics Market Worldwide: Percentage Share of Leading Players for the Years 2003 and 2004 – Schering, Amersham, Bracco, and Others (Revenue Share) (includes corresponding Graph/Chart).....II-17

Table 6: Radiopharmaceutical Medical Diagnostics Market Worldwide: Percentage Market Share of Leading Players for the Years 2003 and 2004 – Amersham, Bristol-Myers Squibb, Tyco/ Mallinckrodt, Inc and Others (Revenue Share) (includes corresponding Graph/Chart).....II-17
1$350
  4. Technology Breakthroughs.....II-183 $300  
   Molecular Imaging Agents: The Outer Limits.....II-18
On Cards: Hyperpolarized Gases as Contrast Agents.....II-18
Imaging Agents Make a Welcome Impact in the Field of Alzheimer’s Disease.....II-18
1$100
   Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging.....II-19
A New Imaging Agent for Radiopharmaceutical Scans.....II-19
Multi-Modal Image Registration: Combating Contrast Medium Inconsistencies.....II-19
1$100
   Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents.....II-20
1$100
  5. Product Overview.....II-2112 $800  
   Contrast Agents.....II-21
Contrast Media: How Do They Function?.....II-21
1$100
   Where Are They Used ?.....II-22
Evolution of Contrast Media: A Profile.....II-22
Bismuth Nitrate: Beginning of Contrast Agents.....II-22
1$100
   Imaging Agents: Significant Developments in the Last Fifty Years.....II-23
Schering Develops First Intravenous Contrast Agent.....II-23
MRI: Creating a New Era for Contrast Agents.....II-23
A Peek into the Finer Points of Differences Among Contrast Media.....II-23
Viscosity.....II-23
Osmolality.....II-23
1$100
   Chemotoxicity.....II-24
Second Generation Non-Ionic Contrast Agents: An Introduction.....II-24
Choice of the Contrast Medium: A Weighty Decision.....II-24
Factors affecting choice of Imaging Agents.....II-24
Taxonomy.....II-24
Types of Contrast Media.....II-24
1$100
   X-Ray Contrast Medium.....II-25
First Generation High Osmolar Contrast Media.....II-25
Second Generation Low Osmolar Contrast Media or LOCM.....II-25
1$100
   Table 7: Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media.....II-26
MRI Contrast Medium.....II-26
1$350
   Role of Contrast Enhancement in MR Angiography (MRA).....II-27
MRI Contrast Agents for the Liver.....II-27
Paramagnetic extracellular contrast agents.....II-27
Hepatobiliary Gadolinium Chelates.....II-27
1$100
   Superparamagnetic Iron Oxide Particles.....II-28
Ultrasound Contrast Medium.....II-28
Ultrasonographic Contrast Media: What Are They?.....II-28
1$100
   Ultrasound Contrast Enhancement in Cardiology.....II-29
Functionalities of Vascular Ultrasound Contrast Agents.....II-29
1$100
   Diagnostic Radiopharmaceuticals.....II-30
Key Radioactive Isotopes used as Diagnostic Radiopharmaceuticals.....II-30
1$100
   A Delineate of Diagnostic Radiopharmaceuticals.....II-31
Diagnostic Radiopharmaceuticals: A Technical Run-Through.....II-31
1$100
   Applications.....II-32
1$100
  6. A Segmental Review.....II-335 $500  
   Contrast Media.....II-33
Popular Brands of Contrast Agents Available Worldwide.....II-33
2$200
   A Peek into Select Imaging Agents Under Clinical Trials Worldwide.....II-35
X-ray Contrast Media.....II-35
Market Scenario.....II-35
1$100
   MRI Contrast Media.....II-36
Market Scenario.....II-36
Ultrasound Contrast Media.....II-36
Market Overview.....II-36
Competitive Scenario.....II-36
Diagnostic Radiopharmaceuticals.....II-36
Market Overview.....II-36
1$100
   Immunoconjugates.....II-37
Market Overview.....II-37
Competitive Scenario.....II-37
1$100
  7. Technology Dynamics.....II-385 $500  
   Proprietary Technologies Making Significant In-Roads.....II-38
Advanced Magnetics’ Proprietary Colloidal Superparamagnetic Particle
  Technology.....II-38
Enzon’s Single Chain Antigen-Binding Technology.....II-38
Immunomedics’ Antibody Technology.....II-38
First Generation.....II-38
Second Generation.....II-38
Third Generation.....II-38
1$100
   NeoRx’s “Painting the Target” Technology.....II-39
Stage – I.....II-39
Stage – II.....II-39
Stage – III.....II-39
Gas Encapsulation Technology for Ultrasound Contrast Media.....II-39
1$100
   Pharmacyclics’ Texaphyrin Technology.....II-40
Regulatory Bodies.....II-40
Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA.....II-40
Entry Barriers.....II-40
Research Driven Markets.....II-40
Highly Competitive Market.....II-40
1$100
   Economies of Scale.....II-41
Substitutes in Agents Manufacturing.....II-41
New X-ray Diagnostic Agents.....II-41
Amide-based Macrocyclic Ligands - Potential MRI Agents.....II-41
Gadolinium (III) Complexes - Potential MRI Contrast Agents.....II-41
Metal-Containing Compounds Act As Potential Contrast Agents.....II-41
Therapeutic Applications.....II-41
Diagnostic Applications.....II-41
1$100
   Magnetic Gels as Potential MRI Contrast Agents.....II-42
PFCs as Diagnostic Contrast Agents.....II-42
1$100
  8. Product Launches.....II-434 $400  
   Bayer to Unleash Radiology Management System.....II-43
Bayer to Unveil Pre-Filled Contrast-Medium Cartridges for MRI.....II-43
Insight Agents to Launch Generic Contrast Media Solutions In Europe.....II-43
Researchers Develop First Biocompatible MRI Contrast Agent.....II-43
Signalomics and Invitrogen Collaborate to Develop Nanocrystal Reagents.....II-43
1$100
   Schering AG Collaborates with Stanford University to Develop Molecular Imaging
  Agent.....II-44
Schering and Avid to Develop Diagnostic Imaging Agents.....II-44
US National Institutes of Health Develops two PET Imaging Agents.....II-44
Bracco Diagnostics Canada Introduces MRI Contrast Agent MultiHance.....II-44
JBCPL Launches Magnilek Contrast Agent.....II-44
Mallinckrodt Launches NeutroSpec™.....II-44
1$100
   Schering AG’s Primovist™ Approved in Sweden.....II-45
Isovue – A Non-ionic Monomeric X-Ray Contrast Agent from Bracco Diagnostics.....II-45
Schering Strengthens Position with MS-325.....II-45
Berlex Launches MRI Contrast Agent.....II-45
Amersham Health Introduces Omnipaque.....II-45
1$100
   Boston Scientific Corp Launches Galaxy System.....II-46
Syncor International Launches F-18 FDG.....II-46
1$100
  9. Recent Industry Activity.....II-4717 $1000  
   Bristol-Myers Squibb Medical Imaging Adopts New Identity, Lantheus Medical
  Imaging.....II-47
Cytogen Corporation to Merge Business with EUSA Pharma Inc.....II-47
Bracco Group Acquires E-Z-EM.....II-47
EPIX Pharmaceuticals to Resubmit New Drug Application (NDA) for Vasovist.....II-47
Bayer Schering, FutureChem Ink Licensing Deal.....II-47
1$100
   NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive Imaging Agent.....II-48
Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals.....II-48
Bracco Diagnostics Inks Agreement with HealthTrust Purchasing Group.....II-48
Bracco Diagnostics Offers MRI Products to HealthTrust Purchasing Group.....II-48
Bayer HealthCare Offers MRI Contrast Agent to HealthTrust.....II-48
Bayer HealthCare Extends Contract with Premier.....II-48
1$100
   Bayer HealthCare Sets Off US Operations.....II-49
Tyco Healthcare Renamed to Covidien Ltd.....II-49
Covidien Offers Imaging Solutions to MedAssets Supply Chain Systems.....II-49
Siemens, M.D. Anderson Cancer Center Set up Research Centre.....II-49
Bayer, Berlex Merge Operations.....II-49
AION Diagnostics Forays Pre-Clinical Imaging Agent Market.....II-49
1$100
   ART Acquires Alerion Biomedical.....II-50
EPIX to Merge with Predix.....II-50
Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories.....II-50
Bracco Diagnostics Inks Agreement with Amerinet Vasovist receives Green Signal in
  Australia.....II-50
AION Diagnostics Develops BioSilicon TM.....II-50
1$100
   Sonazoid Receives Import Approval.....II-51
Schering AG Divests Radiopharmaceutical Business to Ion Beam Applications and Institut
  National des Radioéléments.....II-51
Vasovist Receives European Approval.....II-51
Albany Molecular Research Renews Supply Agreement with GE Healthcare.....II-51
QuantRx Biomedical Corp. Acquires Stake in FluoroPharma.....II-51
Palatin Technologies Withdraws NeutroSpec Imaging Agent.....II-51
1$100
   Diosynth Bags Contract to Produce Imaging Agent.....II-52
GE Healthcare Signs Marketing Agreement with PhotoCure.....II-52
DRAXIMAGE Receives the Green Signal in Europe.....II-52
Daiichi and Sankyo Sign a Merger Deal.....II-52
Bristol Myers and Imcor Pharmaceutical Forge Cross- Licensing Agreement.....II-52
Kereos and Dow to Develop Unique Targeted Imaging Agents.....II-52
1$100
   Bristol-Myers and Kereos to Collaborate on Molecular Imaging Agents.....II-53
GE Acquires Amersham PLC.....II-53
Photogen Technologies Acquires Imagent®.....II-53
Dow and Kereos Collaborate.....II-53
IBC Pharmaceuticals and Schering AG Collaborate on Cancer Research.....II-53
Schering Purchases CIS Bio International.....II-53
1$100
   Imaging Diagnostic Systems to Collaborate with Schering.....II-54
Mallinckrodt Signs Distribution Agreement with Proxima Therapeutics.....II-54
Immunomedics Signs Marketing Agreement with Teva-Tuteur.....II-54
DRAXIS Increases BrachySeed Production.....II-54
1$100
   DRAXIMAGE Obtains FDA Approval for Manufacturing Lyophilized Products.....II-55
Nycomed Amersham Acquires Bruker’s TOMOJET.....II-55
DuPont Acquires Caribbean-PharmaLogic Radiopharmacies.....II-55
Bristol-Myers Squibb Company Acquires DuPont Pharmaceuticals.....II-55
Alliance Pharmaceutical Completes Acquisition of Molecular Biosystems.....II-55
1$100
   GE Medical Acquires Coincidence Technologies.....II-56
Tyco International Acquires Mallinckrodt.....II-56
Zydus Cadila Acquires 27.72 % Stake in German Remedies.....II-56
Schering Acquires Manufacturing Rights of MS-325 from EPIX Medical.....II-56
Zydus Cadila Acquires Five Brands from Asta Medica.....II-56
AxCell BioSciences Forms Joint Venture with Institute for Systems Biology.....II-56
1$100
   Syncor Signs Purchasing Agreements with HSCA.....II-57
Syncor and InSource Health Services Sign Agreement.....II-57
DRAXIS Signs Agreement with BTG for INFECTON.....II-57
Peregrine Pharmaceuticals and Paul Scherrer Institute Expand R&D Agreement.....II-57
Syncor and Broadlane Ink Agreement.....II-57
1$100
   Syncor and Catholic Healthcare West Extend Agreement.....II-58
MedImmune and Targesome Sign R&D Agreement.....II-58
Vital Images Inks an Agreement with E-Z-EM Inc.....II-58
TriPath Imaging and MDS Ink Agreement.....II-58
North American Scientific Forges Strategic Relationship with Certus
  International.....II-58
1$100
   Mediaworks Launches RadiologyWeb.....II-59
Nycomed Amersham Extends Supply Contract with Novation.....II-59
Advanced Magnetics Receives Approval for Feridex.....II-59
Targesome Receives NCI Support for Developing Novel Diagnostic Imaging Agents.....II-59
Bracco Acquires Product Lines and Intellectual Property of Resolution
  Pharmaceuticals.....II-59
1$100
   Guerbet Acquires Oxilan, an X-Ray Contrast Agent from Cook Imaging.....II-60
Nycomed Amersham Imaging Associates with Global Healthcare Exchange.....II-60
Nycomed Amersham and D-Pharm Ally to Develop New Imaging Agents.....II-60
Bracco Group Forges Strategic Alliance with Dyax Corp.....II-60
1$100
   DRAXIS Signs Agreement with Cytogen Corp.....II-61
CV Therapeutics and Fujisawa Healthcare Sign Collaboration Agreement.....II-61
Comprehensive Medical Imaging Signs Agreement with US Diagnostic.....II-61
Syncor International and GE Medical Systems Sign Strategic Agreement.....II-61
1$100
   Guilford Pharmaceuticals Licenses Dopascan to MAP Medical Technologies.....II-62
Cytogen and Advanced Magnetics Sign Agreements.....II-62
Amersham Sells Nycomed Pharma Subsidiary.....II-62
Amersham Renames its Businesses.....II-62
Nycomed Amersham Obtains Approval from FDA for MYOVIEW.....II-62
Schering Obtains Approval for Cancer Imaging Agent.....II-62
1$100
   Datscan Receives European Union Marketing Authorization.....II-63
1$100
  10. Focus on Select Players.....II-645 $500  
   AMAG Pharmaceuticals Inc (USA).....II-64
Amersham Plc (UK).....II-64
1$100
   Bayer Schering Pharma AG (Germany).....II-65
Bayer HealthCare Pharmaceuticals (US).....II-65
Bracco Group (Italy).....II-65
1$100
   E-Z-EM Inc. (USA).....II-66
Covidien (USA).....II-66
Cytogen Corp. (USA).....II-66
1$100
   Daiichi Sankyo Company Limited (Japan).....II-67
Eisai Co., Ltd (Japan).....II-67
EPIX Pharmaceutical Inc. (USA).....II-67
Guerbet Group (France).....II-67
1$100
   Lantheus Medical Imaging (USA).....II-68
1$100
  11. Global Market Perspective.....II-69   
   Table 8: World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-691$350
   Table 9: World Long-term Projections for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-701$350
   Table 10: World 10-Year Perspective for Imaging Agents by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-711$350
   Table 11: World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-721$350
   Table 12: World Long-term Projections for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-731$350
   Table 13: World 10-Year Perspective for Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-741$350
   Table 14: World Recent Past, Current & Future Analysis for Contrast Media by Product Segment – X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-75

Table 15: World Long-term Projections for Contrast Media by Product Segment – X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-75
1$350
   Table 16: World 10-Year Perspective for Contrast Media by Product Segment – Percentage Breakdown of Dollar Sales for X-Ray, MRI and Ultrasound Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-761$350
   Table 17: World Recent Past, Current & Future Analysis for X-Ray Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-771$350
   Table 18: World Long-term Projections for X-Ray Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-781$350
   Table 19: World 10-Year Perspective for X-Ray Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-791$350
   Table 20: World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-801$350
   Table 21: World Long-term Projections for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-811$350
   Table 22: World 10-Year Perspective for MRI Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-821$350
   Table 23: World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-831$350
   Table 24: World Long-term Projections for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-841$350
   Table 25: World 10-Year Perspective for Ultrasound Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-851$350
   Table 26: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region- US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-861$350
   Table 27: World Long-term Projections for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-871$350
   Table 28: World 10-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....II-881$350
III. MARKET81$1950
  1. The United States.....III-123 $1275  
   A. Market Analysis.....III-1
Outlook.....III-1
Growth Stimulants.....III-1
Medical Imaging: Changing the Healthcare Landscape.....III-1
Dynamics of Pricing.....III-1
1$75
   Table 29: Hospital Purchases by GPOs in the United States – Percentage Breakdown by Type for the Year 2002 (includes corresponding Graph/Chart).....III-2
Reimbursements Issues.....III-2
Medicare.....III-2
1$200
   Magnetic Resonance Imaging.....III-3 1$75
   Table 30: Medicare Reimbursements for Brain MRI Procedures for the Year 2006.....III-41$200
   Table 31: Medicare Reimbursements for Breast MRI Procedures for the Year 2006.....III-5
Regulatory Environment.....III-5
1$200
   Provisions Regarding Off-Label Usage of Contrast Media.....III-6
Contrast Media.....III-6
X-ray Contrast Media.....III-6
1$75
   MRI Contrast Media.....III-7
Market Scenario.....III-7
Managed Care Vs MRI Technology Diffusion.....III-7
Ultrasound Contrast Media Market.....III-7
Diagnostic Radiopharmaceuticals.....III-7
Market Scenario.....III-7
Availability of Isotopes: A Tough Challenge.....III-7
1$75
   Select Players.....III-82$150
   Strategic Corporate Developments.....III-1010$525
   Product Launches.....III-202$150
   B. Market Analytics.....III-22
Table 32: US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-22

Table 33: US Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-22
1$200
   Table 34: US Historic Review for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 1999 (includes corresponding Graph/Chart).....III-23

Table 35: US 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-23
1$200
  2. Canada.....III-246 $575  
   A. Market Analysis.....III-24
Outlook.....III-24
Diagnostic Equipment Market.....III-24
LOCM Products Approved in Canada.....III-24
Select Player.....III-24
1$75
   Strategic Corporate Developments.....III-252$150
   B. Market Analytics.....III-27
Table 36: Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-27
1$200
   Table 37: Canadian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-281$200
   Table 38: Canadian 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-29
1$200
  3. Japan.....III-304 $325  
   A. Market Analysis.....III-30
Outlook.....III-30
Reimbursement Issues.....III-30
Select Players.....III-30
1$75
   Strategic Corporate Developments.....III-311$75
   B. Market Analytics.....III-32
Table 39: Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-32

Table 40: Japanese Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-32
1$200
   Table 41: Japanese 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-33
1$200
  4. Europe.....III-3410 $1075  
   A. Market Analysis.....III-34
Outlook.....III-34
Trends.....III-34
Reimbursement.....III-34
Distribution Structure.....III-34
1$75
   Direct Sales.....III-35
License Agreements.....III-35
Distribution Agreements.....III-35
A Price Sensitive Market.....III-35
Table 42: European Contrast Media Market (2005): Average Cost of Contrast Media Per Imaging Procedure.....III-35
1$200
   Table 43: Product Price of Select Contrast Agents in Europe by Company.....III-36
Macro Market Environment.....III-36
Germany.....III-36
1$200
   France.....III-37
United Kingdom.....III-37
Spain & Italy.....III-37
Scandinavia.....III-37
1$75
   Strategic Corporate Developments.....III-38
Product Launch.....III-38
1$75
   B. Market Analytics.....III-39
Table 44: European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-39
1$200
   Table 45: European Long-term Projections for Imaging Agents by Geographic Region – France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-401$200
   Table 46: European 10-Year Perspective for Imaging Agents by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-411$200
   Table 47: European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-42

Table 48: European Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-42
1$200
   Table 49: European 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-43
1$200
  4a. France.....III-444 $450  
   A. Market Analysis.....III-44
Outlook.....III-44
Growth Stimulants.....III-44
Contrast Media.....III-44
Major Player.....III-44
1$75
   Strategic Corporate Developments in the Recent Past.....III-45
B. Market Analytics.....III-45
Table 50: French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-45
1$200
   Table 51: French Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-461$200
   Table 52: French 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-47
1$200
  4b. Germany.....III-485 $375  
   A. Market Analysis.....III-48
Outlook.....III-48
Major Player.....III-48
Strategic Corporate Developments.....III-48
2$150
   Product Launches.....III-501$75
   B. Market Analytics.....III-51
Table 53: German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-51
1$200
   Table 54: German Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-52

Table 55: German 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-52
1$200
  4c. The United Kingdom.....III-535 $525  
   A. Market Analysis.....III-53
Outlook.....III-53
Major Player.....III-53
Strategic Corporate Developments in the Recent Past.....III-53
2$150
   B. Market Analytics.....III-55
Table 56: UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-55
1$200
   Table 57: UK Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-561$200
   Table 58: UK 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-57
1$200
  4d. Italy.....III-585 $500  
   A. Market Analysis.....III-58
Outlook.....III-58
Major Player.....III-58
Strategic Corporate Developments.....III-58
2$150
   B. Market Analytics.....III-60
Table 59: Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-60
1$200
   Table 60: Italian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-611$200
   Table 61: Italian 10-Year Perspective for Imaging Agents by Product Segment-Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-62
1$200
  4e. Spain.....III-633 $425  
   Market Analysis.....III-63
Table 62: Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-63
1$200
   Table 63: Spanish Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-641$200
   Table 64: Spanish 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-65
1$200
  4f. Russia.....III-663 $425  
   Market Analysis.....III-66
Table 65: Russian Recent Past, Current & Future Analysis for Imaging Agents by product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-66
1$200
   Table 66: Russian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-671$200
   Table 67: Russian 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-68
1$200
  4g. Rest of Europe.....III-693 $450  
   A. Market Analysis.....III-69
Outlook.....III-69
Strategic Corporate Developments.....III-69
B. Market Analytics.....III-69
Table 68: Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment-Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-69
1$200
   Table 69: Rest of Europe Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-701$200
   Table 70: Rest of Europe 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-71
1$200
  5. Asia-Pacific.....III-724 $375  
   A. Market Analysis.....III-72
Outlook.....III-72
PET Imaging-An Overview.....III-72
ANSTO: Leading the Radiopharmaceuticals Market.....III-72
Strategic Corporate Developments.....III-72
2$150
   Product Launch.....III-74
B. Market Analytics.....III-74
Table 71: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-74
1$200
   Table 72: Asia-Pacific Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-75

Table 73: Asia-Pacific 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-75
1$200
  6. The Middle East.....III-763 $425  
   Market Analysis.....III-76
Table 74: Middle East Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-76
1$200
   Table 75: Middle East Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-771$200
   Table 76: Middle East 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-78
1$200
  7. Latin America.....III-793 $600  
   Market Analysis.....III-79
Table 77: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-79
1$200
   Table 78: Latin America Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-801$200
   Table 79: Latin American 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart).....III-811$200
IV. COMPETITIVE LANDSCAPE 207$995
  
Total Companies Profiled: 67 (including Divisions/Subsidiaries - 93)

Region/Country                 Players

The United States                 52
Canada                             7
Japan                              6
Europe                            23 
     France                        3
     Germany                       8
     The United Kingdom            6
     Italy                         1
     Spain